Abstract
The diagnosis of drug-induced liver injury (DILI) is challenging and based on complex diagnostic criteria. DILI falls into two main categories i) intrinsic “dose-dependent” Type A reactions ii) “idiosyncratic” or Type B reactions (which are usually not predictable). Idiosyncratic reactions can be immunoallergic (hypersensitivity), or metabolic, although overlap between categories can occur. The aim of this review is to summarise the general view of underlying mechanisms in DILI and to highlight individual risk factors for developing hepatotoxicity. Polymorphisms of bioactivation/ toxification pathways through CYP450 enzymes (Phase I), detoxification reactions (Phase II) and excretion/transport (Phase III) are explored together with immunological factors that might determine DILI. The importance of establishing a multidisciplinary and multi-centric network to promote the understanding and research in hepatotoxicity is underlined. Challenges such as genetic analyses for association studies and whole genome studies, pharmacogenetic testing and future approaches to study DILI are considered. Knowledge regarding these operational mechanisms could provide further insight for the prospective identification of susceptible patients at risk of developing drug-induced hepatotoxicity..
Keywords: Drug-induced liver injury (DILI), molecular mechanism of DILI, genetic polymorphism, Phase I, II and III enzymes, genetic testing
Current Drug Safety
Title: Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review
Volume: 2 Issue: 2
Author(s): Ketevan Pachkoria, M. Isabel Lucena, Mariam Molokhia, Raquel Cueto, Alfonso Serrano Carballo, Alfonso Carvajal and Raul J. Andrade
Affiliation:
Keywords: Drug-induced liver injury (DILI), molecular mechanism of DILI, genetic polymorphism, Phase I, II and III enzymes, genetic testing
Abstract: The diagnosis of drug-induced liver injury (DILI) is challenging and based on complex diagnostic criteria. DILI falls into two main categories i) intrinsic “dose-dependent” Type A reactions ii) “idiosyncratic” or Type B reactions (which are usually not predictable). Idiosyncratic reactions can be immunoallergic (hypersensitivity), or metabolic, although overlap between categories can occur. The aim of this review is to summarise the general view of underlying mechanisms in DILI and to highlight individual risk factors for developing hepatotoxicity. Polymorphisms of bioactivation/ toxification pathways through CYP450 enzymes (Phase I), detoxification reactions (Phase II) and excretion/transport (Phase III) are explored together with immunological factors that might determine DILI. The importance of establishing a multidisciplinary and multi-centric network to promote the understanding and research in hepatotoxicity is underlined. Challenges such as genetic analyses for association studies and whole genome studies, pharmacogenetic testing and future approaches to study DILI are considered. Knowledge regarding these operational mechanisms could provide further insight for the prospective identification of susceptible patients at risk of developing drug-induced hepatotoxicity..
Export Options
About this article
Cite this article as:
Pachkoria Ketevan, Isabel Lucena M., Molokhia Mariam, Cueto Raquel, Serrano Carballo Alfonso, Carvajal Alfonso and Andrade J. Raul, Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review, Current Drug Safety 2007; 2 (2) . https://dx.doi.org/10.2174/157488607780598287
DOI https://dx.doi.org/10.2174/157488607780598287 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [ Proteases and Phospholipases in CNS Disorders Guest Editor: Swapan K. Ray ]
CNS & Neurological Disorders - Drug Targets The Physiological Basis and Nutritional Function of Alpha-ketoglutarate
Current Protein & Peptide Science Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients
Current Pharmaceutical Design Alternative Approach for Mitigation of Doxorubicin-Induced Cardiotoxicity using Herbal Agents
Current Clinical Pharmacology TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Current Drug Targets A Critical Evaluation of Adenosine A2A Receptors as Potentially “Druggable” Targets in Huntingtons Disease
Current Pharmaceutical Design Current Status of Rho-Associated Kinases (ROCKs) in Coronary Atherosclerosis and Vasospasm
Cardiovascular & Hematological Agents in Medicinal Chemistry Knockdown of C-C Chemokine Receptor 5 (CCR5) is Protective Against Cerebral Ischemia and Reperfusion Injury
Current Neurovascular Research Therapeutic Modulation of Coagulation and Fibrinolysis in Acute Lung Injury and the Acute Respiratory Distress Syndrome
Current Pharmaceutical Biotechnology Female Infertility and Antioxidants
Current Women`s Health Reviews Group VI Phospholipases A2: Homeostatic Phospholipases with Significant Potential as Targets for Novel Therapeutics
Current Drug Targets PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Effects of Oxymatrine from Ku Shen on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Placental Hypoxia Developed During Preeclampsia Induces Telocytes Apoptosis in Chorionic Villi Affecting The Maternal-Fetus Metabolic Exchange
Current Stem Cell Research & Therapy Ischemic Post-Conditioning Partially Reverses Cell Cycle Reactivity Following Ischemia/Reperfusion Injury: A Genome-Wide Survey
CNS & Neurological Disorders - Drug Targets An Old Drug with a New Purpose: Cardiovascular Actions of Acetaminophen (Paracetamol)
Current Drug Targets - Cardiovascular & Hematological Disorders Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research Therapeutical Relevance of MAP-Kinase Inhibitors in Renal Diseases: Current Knowledge and Future Clinical Perspectives
Current Medicinal Chemistry Role of Carbon Monoxide in Vascular Diseases
Current Pharmaceutical Biotechnology Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease
Current Topics in Medicinal Chemistry